Respiratory disease research will be the focus for the 10th year of the awards

DULUTH, Ga. (June 19, 2020) —Boehringer Ingelheim is accepting proposals for the 2020 Advancement in Equine Research Awards for Equine Respiratory Disease Research.

“Boehringer Ingelheim recognizes the importance of bringing attention to equine research that can help protect and promote the overall health and well-being of the horse,” says Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim. “As we enter our 10th year of supporting the awards, we’re pleased to announce the call for proposals from both public and private researchers studying equine infectious respiratory disease and equine asthma syndrome. Previous award recipients have leveraged new and emerging science to discover scientific breakthroughs to improve equine health.”

Veterinarians, diagnosticians, public and private researchers in the United States, Canada and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment and understanding of equine disease. Boehringer Ingelheim will present five separate $15,000 awards focused on two specific disease topics.

Proposals must address one of the two following focus areas for consideration:

  • Equine Infectious Respiratory Disease
  • Equine Asthma Syndrome

Proposals must be submitted by Sept.15, 2020, and will be reviewed by an independent review board that consists of renowned equine industry professionals, including practicing veterinarians and researchers. The board will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality and scientific quality. The awards will be announced at the 66th annual American Association of Equine Practitioners Convention Dec.5-9, 2020.

To participate in the awards program, submit a proposal, cover letter and curriculum vitae by Sept. 15, 2020 to:

Boehringer Ingelheim Animal Health
Attn: Dr. Steve Grubbs
The 2020 Advancement in Equine Research Awards
3902 Gene Field Rd.
St. Joseph, MO 64506

The Boehringer Ingelheim Advancement in Equine Research Awards were launched in 2011 to support veterinary research that results in practical applications for or insights into important equine infectious diseases and improves the quality of life for all horses. More than $600,000 has been awarded to date for emerging science in equine research.

For more information and complete submission instructions, please visit


About Boehringer Ingelheim Animal Health

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, our 10,000 global employees are dedicated to enhancing the well-being of both –through science and innovation, as well as through their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life-and society-threatening diseases.

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit, or

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros)in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at or in our annual report:

©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0159-2020